Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Innovision IPO Review: APPLY or AVOID? | What You Need to Know

By Jagat Joshi
March 13, 2026

Innovision Limited IPO is one of the most-awaited IPOs of 2026 and is finally launching. Innovision, founded in 2007, is one of the leading companies that manages Tall Plaza, deploys private security guards, provides manpower services, and offers skill development training.

The IPO will be open for subscription on March 10, 2026, and close on March 17, 2026. The Innovision IPO price band is set between ₹494 to ₹519 per share, with a face value of ₹10 each. As per the RHP, the company plans to raise around ₹306 crores through an Initial public offering (IPO).

Review IPO Details GMP Messages Subscription Allotment Listing

As an investor, it can be very challenging to decide whether the Innovision IPO is a good or bad investment. Not anymore, as in this blog, we will provide you with all the necessary details related to the Innovision IPO to help you decide whether you should Apply or Not. Read on to know the IPO risks, strengths, valuation, financial details, and expert opinion to make your investment decision better.

Strengths:

The firm operates 39 offices across India, offering its services to 23 states and 5 union territories.

Innovision offers various Manpower services, which include private security, IFM services, and manpower sourcing and payroll solutions catering to different sectors.
The company is backed by experienced promoters who have 15 years of industry experience.

The firm has an in-house team of 100 professionals who manage staff and recruitment, without relying on 3rd-party recruitment.

Over the last 3 years, Innovision has had a good Return on Equity (ROE) of 33.0%.

Weaknesses:

Instead of long-term, the firm will use the funds raised from the fresh issue towards short-term capital requirements and debt repayment only.

The company generates around 56% of revenue from the NHAI tender for Tall Plaza Management. If it failed to secure more contracts from NHAI clients for its Tall plaza business can affect the company’s financials and revenue.

Innovision mainly depends on its manpower services; being unable to keep or attract new workers or staff can impact business growth.

Around 90% of its revenue comes from toll plaza management and manpower services; a decline in the demand for such services can negatively affect the business.

Innovision IPO Review

Reviewer	Recommendation
IPO Watch	Avoid
Capital Market	Avoid
Swastika Investmart Ltd	Avoid
Ventura Securities Limited	Apply

Promoters & Track Records, if any

Lt Col Randeep Hundal, aged 49 years, is one of the promoters and is also the Chairman and Managing Director. He holds 9,449,986 equity shares, representing 49.99% of pre-offer shareholding capital.

Uday Pal Singh, aged 48 years, is one of the promoters and is also the Whole Time Director and Chief Executive Officer of the Company. He holds 9,449,958 equity shares, representing 49.99% of pre-offer shareholding capital.

Peer Comparison with the Company

Name of the Company	Face Value(₹)	EPS (₹)	RONW (%)	P/E Ratio	NAV(₹)
Innovision	10	15.62	35.45%	35.69	43.32
Listed Peers
Krystal IntegratedServicesLimited	10	44.61	14.30%	13.47	312.92
UpdaterServicesLimited	10	17.70	12.33%	8.62	144.07
SIS Limited	5	0.81	0.49%	401.85	166.79
Quess Corp Limited	10	3.07	4.23%	63.37	72.92
HighwayInfrastructure Ltd	5	3.40	19.03%	15.15	20.37

Industry Peer Group P/E ratio

The peer group P/E ranges from the lowest of 8.62 for Krystal Integrated Services Limited to the highest of 401.85 for SIS Limited, with an average P/E of 100.49.

Expansion

The proceeds of ₹51 crore raised from the fresh issue will be utilized towards the repayment/prepayment of existing debt taken by the company.

The funds of ₹119 crore from the fresh issue will be used towards the working capital requirement of the company.

Lastly, the remaining funds will be utilized for the general corporate purposes.

Innovision IPO — Should You Apply or Not?

Started its business as a private security services company, and now focuses on toll plaza management and manpower services, Innovision IPO is opening for subscription on the 10th of March. Under the manpower services, they offer security services, cleaning, housekeeping, support staff, and recruitment solutions for various industries like healthcare, warehousing and logistics, government departments, retail, and BFSI.

As of January 2026, Innovision Limited has worked with 180 clients across various sectors. Coming to its financials, in FY25, the revenue surged to ₹895.95 crore, which was ₹257.62 crore in FY23, indicating a strong CAGR of around 87%, strengthening its market presence. Moreover, its PAT also grew by ₹29.02 crore in FY25, from ₹8.88 crore in FY23, reflecting a healthy GAGR of 81%. Furthermore, the company’s EPS and margin are also expanding. However, high dependency on NHAI tenders for toll plaza management, and only 1% allocation for QIB investors, can present risk and affect investors’ confidence.

Now coming to its valuation, on the upper price band, the Innovision IPO is trading at a PE of 35.69x. When compared to its peer groups from RHP, the valuation seems neither too expensive nor too cheap. As of March 9, there is no movement in the Innovision IPO GMP, indicating a neutral sentiment in the market. Connect with IPO Watch to get the latest updates on GMP and IPO insights.

The growing toll plaza management and manpower services businesses, healthy financials, experienced promoters, and if GMP and subscription numbers stay in support, then investors can apply for short-term goals. But, high dependency on contract renewals, 1% QIB allocation, and expensive valuations must not be ignored by the investors before subscribing.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.